A quiet revolution in obesity management crossed a significant European threshold this week as France began reimbursing the blockbuster drugs Mounjaro and Wegovy for patients with severe obesity. The decision, the first of its kind on the continent, marks a turning point in how health systems confront a chronic condition that has long defied effective medical intervention. Parisian endocrinologists report a surge of interest from patients, many of whom have waited months for access to the weekly injections that mimic a gut hormone to suppress appetite. For a nation grappling with rising obesity rates, the move signals a shift from viewing these medications as lifestyle aids to recognising them as essential therapeutic tools.

Across the Atlantic, where one in eight American adults has already tried a GLP-1 drug, the societal impact is reverberating far beyond the doctor’s office. Market analysts in New York note a remarkable boom in the sale of gourmand perfumes—fragrances laden with notes of caramel, vanilla, and toasted pistachio—as users report transferring their cravings for sugar onto scent. Industry observers see this as more than a fleeting trend: it is reshaping global fragrance development, with European maisons rushing to bottle the olfactory equivalent of a patisserie window. The phenomenon has sparked debate about the unexpected ways appetite-modifying therapies are rewiring sensory pleasures.

Yet the most profound implications may lie in science, not shopping. Researchers from Stockholm to San Diego are investigating whether GLP-1 agonists, initially developed for diabetes, can treat a startling array of conditions. Early studies hint at benefits for everything from neurodegenerative diseases and cancer to depression, addiction, and endometriosis. While some findings are genuinely exciting, clinicians in London caution against hype, noting that the mechanisms by which these drugs influence brain and body remain only partially understood. The rush to embrace them as panaceas risks obscuring the need for rigorous, long-term evidence.

In a striking parallel, a team in Winnipeg, Canada, has upended conventional thinking about a drug that sits in millions of bathroom cabinets. Tamiflu, the antiviral long prescribed for influenza, appears to protect brain tissue and aid motor recovery after ischaemic stroke, according to new research led by Dr. Shayan Amiri. If confirmed, oseltamivir could offer a cheap, widely available neuroprotective agent—an echo of how aspirin’s clinical repertoire expanded well beyond its original use. The discovery underscores a broader pattern: old molecules, when examined through a fresh lens, can yield therapies that challenge the boundaries of specialist medicine.

These converging narratives point to an era of therapeutic repurposing that may rival blockbuster drug development. For health systems from Paris to Washington, the immediate challenge is managing the cost and demand surge for GLP-1 agonists, even as supply chains strain under global enthusiasm. Longer term, the tantalising prospect is a pharmacopeia in which yesterday’s flu pill or diabetes injection becomes tomorrow’s stroke shield or addiction treatment. Whether such promise survives the crucible of clinical trials remains an open question, but the scientific and commercial momentum suggests the pharmaceutical landscape is being reshaped from the bottom up—one unexpected finding at a time.